<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326612</url>
  </required_header>
  <id_info>
    <org_study_id>15275</org_study_id>
    <nct_id>NCT00326612</nct_id>
  </id_info>
  <brief_title>Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures</brief_title>
  <official_title>Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Primary Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a randomized controlled trial comparing the use of nasal
      midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute
      seizure activity in children under the age of 18 years with epilepsy in the community
      setting. The primary hypothesis is that nasal midazolam will be more effective and have
      shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses
      are that patients treated with nasal midazolam will have fewer respiratory complications,
      emergency department visits, and admissions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a prospective randomized controlled study.

      Study Procedures: Parents/guardians will be provided with a stopwatch to help record seizure
      times on the &quot;Parent Form&quot;. All parents of children who have a seizure lasting longer than
      five minutes will be randomized to treat their seizure with the study medication (either
      rectal diazepam or nasal midazolam). If a parent treats a child with a study medication for
      seizure activity they are required to call &quot;911&quot;. Families will be instructed to only give
      one dose of the study medication. If the seizure persists, EMS may give a second medication
      and transport the patient to the ED as per their established protocol. All parents/guardians
      who participate in this study will be asked to fill out a &quot;Pre-study Form&quot; (to be filled out
      during enrollment into the study) and a &quot;Parent Form&quot; for every seizure that is treated with
      the study medication. They will be given a stamped returned envelope to return the
      questionnaire. Once the study medication is used once, they will be done with the study. Any
      further need of home rescue medications to treat acute seizure activity will be coordinated
      by their neurologist. If questions arise, a study coordinator will be available by phone. In
      addition, parents/guardians will be contacted by phone every two months and questioned at
      clinic visits to audit compliance of reporting of seizures/hospitalizations, adverse events
      and answer any questions that arise. The study packet also instructs all families to call the
      study coordinator immediately if any expected or unexpected complication occurs. The study
      coordinator will be called on all ED visits and hospitalizations. We will then collect and
      analyze adverse events to compare them between the two groups. Any ER visit or
      hospitalization will be considered an adverse event and will be analyzed for its relationship
      to the seizure or medication. All adverse events will be reported to the IRB. See Table 1 for
      doses for the two study medications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Seizure After Study Medication Administration</measure>
    <time_frame>24 hours</time_frame>
    <description>Length of seizure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression Requiring Intubation</measure>
    <time_frame>24 hours</time_frame>
    <description>Respiratory depression was defined as intubation at Emergency Department discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.</measure>
    <time_frame>24 hours</time_frame>
    <description>Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Intranasal Midazolam 0.2mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GIve once for seizure longer than 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Diazepam 0.3-0.5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Given once for seizure longer than 5 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.</description>
    <arm_group_label>Intranasal Midazolam 0.2mg/kg</arm_group_label>
    <other_name>Diastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.</description>
    <arm_group_label>Rectal Diazepam 0.3-0.5 mg/kg</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children seventeen years and under will be identified through a Pediatric Neurology
             clinic at Primary Children's Medical Center,

          -  Known seizure disorder, AND

          -  Either have or will be prescribed a rescue anti-epileptic (rectal diazepam, or
             Diastat) for home use by their neurologist.

        Exclusion Criteria:

          -  The neurologist does not prescribe a rescue medication for home use,

          -  18 years of age or older,

          -  They have absence seizures, OR

          -  They have been prescribed lorazepam for home use for seizure activity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maija Holsti, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Filloux, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Schunk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harbord MG, Kyrkou NE, Kyrkou MR, Kay D, Coulthard KP. Use of intranasal midazolam to treat acute seizures in paediatric community settings. J Paediatr Child Health. 2004 Sep-Oct;40(9-10):556-8.</citation>
    <PMID>15367152</PMID>
  </reference>
  <reference>
    <citation>Starreveld E, Starreveld AA. Status epilepticus. Current concepts and management. Can Fam Physician. 2000 Sep;46:1817-23. Review.</citation>
    <PMID>11013800</PMID>
  </reference>
  <reference>
    <citation>Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure. 2000 Sep;9(6):417-22.</citation>
    <PMID>10985999</PMID>
  </reference>
  <reference>
    <citation>Jeannet PY, Roulet E, Maeder-Ingvar M, Gehri M, Jutzi A, Deonna T. Home and hospital treatment of acute seizures in children with nasal midazolam. Eur J Paediatr Neurol. 1999;3(2):73-7.</citation>
    <PMID>10700542</PMID>
  </reference>
  <reference>
    <citation>Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA. 1993 Aug 18;270(7):854-9. Review.</citation>
    <PMID>8340986</PMID>
  </reference>
  <reference>
    <citation>Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997 Apr;13(2):92-4.</citation>
    <PMID>9127414</PMID>
  </reference>
  <reference>
    <citation>Fişgin T, Gürer Y, Senbil N, Teziç T, Zorlu P, Okuyaz C, Akgün D. Nasal midazolam effects on childhood acute seizures. J Child Neurol. 2000 Dec;15(12):833-5.</citation>
    <PMID>11198507</PMID>
  </reference>
  <reference>
    <citation>Fişgin T, Gurer Y, Teziç T, Senbil N, Zorlu P, Okuyaz C, Akgün D. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002 Feb;17(2):123-6.</citation>
    <PMID>11952072</PMID>
  </reference>
  <reference>
    <citation>Kutlu NO, Yakinci C, Dogrul M, Durmaz Y. Intranasal midazolam for prolonged convulsive seizures. Brain Dev. 2000 Sep;22(6):359-61.</citation>
    <PMID>11042416</PMID>
  </reference>
  <reference>
    <citation>Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000 Jul 8;321(7253):83-6.</citation>
    <PMID>10884257</PMID>
  </reference>
  <reference>
    <citation>Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Intranasal midazolam as a treatment of autonomic crisis in patients with familial dysautonomia. Pediatr Neurol. 2000 Jan;22(1):19-22.</citation>
    <PMID>10669200</PMID>
  </reference>
  <reference>
    <citation>Lahat E, Goldman M, Barr J, Eshel G, Berkovitch M. Intranasal midazolam for childhood seizures. Lancet. 1998 Aug 22;352(9128):620.</citation>
    <PMID>9746026</PMID>
  </reference>
  <reference>
    <citation>Lahat E. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997 Dec;13(6):449.</citation>
    <PMID>9435015</PMID>
  </reference>
  <reference>
    <citation>McGlone R, Smith M. Intranasal midazolam. An alternative in childhood seizures. Emerg Med J. 2001 May;18(3):234.</citation>
    <PMID>11354231</PMID>
  </reference>
  <reference>
    <citation>Rainbow J, Browne GJ, Lam LT. Controlling seizures in the prehospital setting: diazepam or midazolam? J Paediatr Child Health. 2002 Dec;38(6):582-6.</citation>
    <PMID>12410871</PMID>
  </reference>
  <reference>
    <citation>Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999 Feb 20;353(9153):623-6.</citation>
    <PMID>10030327</PMID>
  </reference>
  <reference>
    <citation>Wallace SJ. Nasal benzodiazepines for management of acute childhood seizures? Lancet. 1997 Jan 25;349(9047):222.</citation>
    <PMID>9014904</PMID>
  </reference>
  <reference>
    <citation>Wroblewski BA, Joseph AB. The use of intramuscular midazolam for acute seizure cessation or behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol. 1992 Feb;15(1):44-9.</citation>
    <PMID>1576597</PMID>
  </reference>
  <reference>
    <citation>Pellock JM. Status epilepticus in children: update and review. J Child Neurol. 1994 Oct;9 Suppl 2:27-35. Review.</citation>
    <PMID>7806783</PMID>
  </reference>
  <reference>
    <citation>Verity CM. Do seizures damage the brain? The epidemiological evidence. Arch Dis Child. 1998 Jan;78(1):78-84. Review.</citation>
    <PMID>9534684</PMID>
  </reference>
  <reference>
    <citation>Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol. 1995 Apr;12(3):213-6.</citation>
    <PMID>7619187</PMID>
  </reference>
  <reference>
    <citation>Knoester PD, Jonker DM, Van Der Hoeven RT, Vermeij TA, Edelbroek PM, Brekelmans GJ, de Haan GJ. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002 May;53(5):501-7.</citation>
    <PMID>11994056</PMID>
  </reference>
  <reference>
    <citation>Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004 Apr;5(2):253-5.</citation>
    <PMID>15123028</PMID>
  </reference>
  <reference>
    <citation>Vilke GM, Sharieff GQ, Marino A, Gerhart AE, Chan TC. Midazolam for the treatment of out-of-hospital pediatric seizures. Prehosp Emerg Care. 2002 Apr-Jun;6(2):215-7.</citation>
    <PMID>11962570</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2006</study_first_submitted>
  <study_first_submitted_qc>May 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <results_first_submitted>March 10, 2011</results_first_submitted>
  <results_first_submitted_qc>September 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2011</results_first_posted>
  <last_update_submitted>September 19, 2011</last_update_submitted>
  <last_update_submitted_qc>September 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Maija Holsti</investigator_full_name>
    <investigator_title>Associate Professor Division of Pediatric Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from a pediatric Neurology clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Midazolam</title>
          <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
        </group>
        <group group_id="P2">
          <title>Rectal Diazepam</title>
          <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>They did not have a seizure requiring tx</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Midazolam</title>
          <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
        </group>
        <group group_id="B2">
          <title>Rectal Diazepam</title>
          <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="5.0"/>
                    <measurement group_id="B2" value="7.3" spread="4.5"/>
                    <measurement group_id="B3" value="7.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Seizure After Study Medication Administration</title>
        <description>Length of seizure.</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>Median time to seizure cessation from medication administration to seizures stop time.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>Median time to seizure cessation from medication administration to seizures stop time.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Seizure After Study Medication Administration</title>
          <description>Length of seizure.</description>
          <population>Analysis was per protocol</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="15.7" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="4.3" spread="11.3" lower_limit="2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Depression Requiring Intubation</title>
        <description>Respiratory depression was defined as intubation at Emergency Department discharge.</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>Patients who required oxygen at discharge from the Emergency Department</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>Includes intubation</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Depression Requiring Intubation</title>
          <description>Respiratory depression was defined as intubation at Emergency Department discharge.</description>
          <population>Analysis was per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication</title>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>67.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.</title>
        <description>Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department.</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Midazolam</title>
            <description>Patients who required oxygen at discharge from the Emergency Department</description>
          </group>
          <group group_id="O2">
            <title>Rectal Diazepam</title>
            <description>Includes intubation</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.</title>
          <description>Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department.</description>
          <population>Analysis was per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>140.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Midazolam</title>
          <description>0.2 mg/kg Intranasal Midazolam for a seizure longer than 5 minutes</description>
        </group>
        <group group_id="E2">
          <title>Rectal Diazepam</title>
          <description>0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maija Holsti, MD, MPH</name_or_title>
      <organization>DIvision of Pediatric Emergency Medicine</organization>
      <phone>801-587-7450</phone>
      <email>maija.holsti@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

